Core Insights - Medicus Pharma Ltd. has appointed Andrew Smith as Chief Operating Officer, bringing over three decades of experience in asset management and financial operations [2][3] - The company is actively engaged in clinical development, particularly with its SKNJCT-003 Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) using novel Doxorubicin Microneedle Arrays (D-MNA) [4][8] Company Leadership - Andrew Smith's previous roles include Chief Executive of SR Asset Management and Co-Head of Americas at Aberdeen Asset Management, highlighting his extensive leadership experience [2][3] - Dr. Raza Bokhari, Executive Chairman and CEO, expressed confidence in Smith's expertise as the company expands its operations across three continents [3] Clinical Development Updates - The SKNJCT-003 Phase 2 clinical study has randomized over 50 of the 90 expected patients, with a positive interim analysis showing more than 60% clinical clearance [4][8] - The study is being conducted at nine clinical sites across the United States, having commenced patient randomization in August 2024 [4] - The investigational review board has increased the participant count for SKNJCT-003 from 60 to 90 subjects, and the company is also expanding clinical trial sites in Europe [4] Additional Clinical Studies - Medicus Pharma is conducting another clinical study, SKNJCT-004, in the United Arab Emirates, which aims to randomize 36 patients across four sites [5] - The principal investigator for the UAE study is Cleveland Clinic Abu Dhabi, with coordination by Insights Research Organization and Solutions [5] Acquisition Plans - The company has entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix for advanced prostate cancer patients [6][9] - The acquisition is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [9]
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer